Nephros's OLpur MD220 diafilters are currently approved in the European Union and Canada. Net diafilter revenues for the nine months ended September 30, 2008 were $920,000 compared to $755,000 in the corresponding period of 2007, an increase of approximately $165,000 or 22%. The increase is due to increased sales of the OLpur MD190 and MD220 diafilters in Europe.
"Physician interest in the Nephros ESRD products continues to be strong; the 510k submission for FDA approval of Nephros's products represents an important milestone toward bringing HDF therapy to the U.S.," said Eric A. Rose, M.D., a member of Nephros's Board of Directors.
Dual Stage Ultrafilters
Nephros has filed a 510k application for approval to market its Dual Stage Ultrafilters (DSU) to dialysis clinics. "We are seeing a great interest for ultra pure water in dialysis centers for water polishing applications," said Mr. Elgin.
Nephros is developing improvements to the functionality of its water ultrafiltration products and has applied for water filter performance certifications from NSF International, an independent non-profit product evaluation laboratory. Nephros currently anticipates completion of required NSF testing in early 2009.
In the third quarter, Nephros recorded initial revenues of $9,000 from the sale of DSU water filtration products in the U.S. Nephros expects DSU sales to represent an increasing percentage of Nephros's revenue mix going forward.
Nephros has launched two new products aimed at preventing the risk of water borne diseases at the point of use. The Nephros Protect! Kit, for showers and sinks, and t
|SOURCE Nephros, Inc.|
Copyright©2008 PR Newswire.
All rights reserved